New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Arcus Biosciences announced the publication of research in Nature linking HIF-2a biology with clinical activity for casdatifan in advanced kidney cancer. The study showed that deep suppression of serum EPO correlated with better outcomes, with a pooled analysis showing a median progression-free survival of 12.2 months in heavily pre-treated patients.
Key figures
- Drug Name
- Casdatifan (AB521)
- Phase Of Trial
- Phase 3 (ongoing PEAK-1), Phase 2/3 (ARC-20)
- Patients pooled n
- 121
- Orr pooled percent
- 31%
- Orr 100mg qd percent
- 35%
- Median pfs pooled months
- 12.2
- Pfs rate 12mo 100mg qd percent
- 60%
- Median pfs 100mg qd jan26 months
- 15.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.